NCT06082635 2025-05-18
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Shenzhen TargetRx Co., Ltd.
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT04507919 2024-11-12
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Novartis
No longer available